Why Rhythm Pharmaceuticals Shares Are Falling
- The FDA has extended the review period for Rhythm Pharmaceuticals Inc's (Get Free Alerts for RYTM) supplemental marketing application for Imcivree (setmelanotide) for obesity and control of hunger with Bardet-Biedl Syndrome (BBS) or Alström syndrome.
- The Prescription Drug User Fee Act (PDUFA) goal date has been revised to June 16, 2022, from March 16.
- FDA requested additional subgroup analyses of the clinical efficacy data from Rhythm's Phase 3 pivotal trial in BBS and Alström syndrome.
- No new data were requested. The additional information has been deemed a 'major amendment' to the sNDA, which requires extra time to review.
- The major amendment did not include any information relating to the safety or manufacturing of setmelanotide.
- Rhythm also withdrew Alström syndrome indication from its pending Type II variation application to the European Medicines Agency for setmelanotide for obesity and control of hunger in adult & pediatric patients six years of age and older with BBS.
- The Company continues to evaluate the next steps relative to seeking marketing authorization for use in patients with Alström syndrome in the European Union.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.